TrialCancer immunology research2020
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Anna Pavlick et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
53 papers cite it
this papercites it